Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
Public ClinicalTrials.gov record NCT00097942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients With Persistent Residual Symptoms
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized that adjunctive therapy with memantine will reduce NMDA receptor hyperactivity, improving signal to noise ratio and thereby improving cognitive symptoms.
Study identification
- NCT ID
- NCT00097942
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2004
- Primary completion
- Aug 31, 2005
- Completion
- Aug 31, 2005
- Last update posted
- Mar 4, 2012
2004 – 2005
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Synergy Clinical Research | National City | California | 91950 | — |
| VA San Diego Healthcare System | San Diego | California | 92161 | — |
| University of Miami Jackson Memorial Hospital | Miami | Florida | 33136 | — |
| University of Iowa Psychiatric Research | Iowa City | Iowa | 52242 | — |
| CBH Health, LLC | Rockville | Maryland | 20850 | — |
| Metropolitan Psychiatric Center | St Louis | Missouri | 63112 | — |
| Dartmouth Hitchcock Medical School | Lebanon | New Hampshire | 03755 | — |
| Nathan Kline Institute | Orangeburg | New York | 10962 | — |
| Duke University John Umstead Hospital | Butner | North Carolina | 27509 | — |
| UNC - Chapel Hill, Clinical Research Unit | Raleigh | North Carolina | 27699-3601 | — |
| University of Cincinnati Medical Science Building | Cincinnati | Ohio | 45267-0559 | — |
| University Hills Clinical Research | Irving | Texas | 75062 | — |
| Medication Research Clinic | San Antonio | Texas | 78207 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00097942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2012 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00097942 live on ClinicalTrials.gov.